No insider purchase over the last 90 days. The latest, by 최영기, was filed 02 Jul 2026.
Who traded when
BuySale+21 other insiders
Since the insiders bought
- -7.9%Entry ₩81,500 · Close 30 Oct 2026 ₩75,100
- -10.2%Entry ₩83,600 · Close 30 Oct 2026 ₩75,100
- -11.5%Entry ₩84,900 · Close 30 Oct 2026 ₩75,100
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Yuhan Corporation Buy (bullish), based on 17 analysts. Average price target: ₩112,059.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 300 sharesShareKRXDART:20260702000551Canonical exit: 30 Sept 2026 (T+90)
- 200 sharesShareKRXDART:20260630000106Canonical exit: 28 Sept 2026 (T+90)
- 516 sharesShareKRXDART:20260625000160Canonical exit: 23 Sept 2026 (T+90)
- 300 sharesShareKRXDART:20260615000122Canonical exit: 13 Sept 2026 (T+90)
- 4,039,408 sharesKRXDART:20260608000028Canonical exit: 6 Sept 2026 (T+90)
- 200 shares@ ₩85,300.000.0003% mcap100.0% of flowShareKRXDART:20260601001839Canonical exit: 27 Aug 2026 (T+90)
- 100 sharesShareKRXDART:20260527000232Canonical exit: 24 Aug 2026 (T+90)
- 300 shares@ ₩90,900.000.0005% mcap27.3% of flowShareKRXDART:20260511000017Canonical exit: 5 Aug 2026 (T+90)
- 300 shares@ ₩90,800.000.0005% mcap100.0% of flowShareKRXDART:20260511000027Canonical exit: 5 Aug 2026 (T+90)
- 4,006,483 shares6.61% mcap100.0% of flowKRXDART:20260511000534Canonical exit: 9 Aug 2026 (T+90)
- 100 shares@ ₩91,000.000.0002% mcap40.2% of flowShareKRXDART:20260511000013Canonical exit: 5 Aug 2026 (T+90)
- 130 shares@ ₩93,400.000.0002% mcap100.0% of flowShareKRXDART:20260506000356Canonical exit: 2 Aug 2026 (T+90)
- 300 shares@ ₩91,700.000.0004% mcap37.8% of flowShareKRXDART:20260506000336Canonical exit: 4 Aug 2026 (T+90)
- 300 shares@ ₩94,711.000.0005% mcap100.0% of flowShareKRXDART:20260428000045Canonical exit: 27 Jul 2026 (T+90)
- 300 shares@ ₩97,100.000.0005% mcap100.0% of flowShareKRXDART:20260427000128Canonical exit: 22 Jul 2026 (T+90)
- 162 shares@ ₩97,600.000.0002% mcap37.4% of flowShareKRXDART:20260427000059Canonical exit: 21 Jul 2026 (T+90)
- 300 shares@ ₩91,700.000.0004% mcap27.0% of flowShareKRXDART:20260421000010Canonical exit: 14 Jul 2026 (T+90)
- 100 shares@ ₩97,000.000.0002% mcap100.0% of flowShareKRXDART:20260420000027Canonical exit: 16 Jul 2026 (T+90)
- 314 shares@ ₩97,000.000.0005% mcap100.0% of flowShareKRXDART:20260417000224Canonical exit: 16 Jul 2026 (T+90)
- 300 shares@ ₩97,500.000.0005% mcap100.0% of flowShareKRXDART:20260417000222Canonical exit: 16 Jul 2026 (T+90)
25 of 113 declarations
About Yuhan Corporation
Of the 108 insider filings recorded at Yuhan Corporation (유한양행), 95 are purchases and 7 are sales, so purchases make up 93% of open-market trades. The largest was filed by 지케이에셋 on May 11, 2026, for EUR 194,556,419, far ahead of the following ones: EUR 27,065 from 조민철 (상무) on April 14, 2026 and EUR 26,947 from 박찬환 (상무) on April 9, 2026. The median of the 32 purchases with an amount is EUR 15,978.
From April 9 to May 7, 2026, 20 filers bought within the same 30-day window, for EUR 322,310 in total. 김열홍 (사장) accounts for 49 filings on their own, all of them purchases; 국민연금공단 (대량보유자) has 9, of which 7 are sales.
Read moreShow less
This South Korean health care company has a market capitalisation of KRW 6,459.6 billion, and insiders hold 31.3% of it. The year 2026 holds 40 filings, against 6 in 2025, and 38 of the 40 filings of the last twelve months are purchases. Filings appear a median of 3 days after the trade. For purchases, a 90-day result is stored (74 cases): a median of -3.4%, with 42% of results positive, recorded past results and not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
